Recent advances in the treatment of multiple myeloma

Current Opinion in Hematology

Volumn 6, Issue 4, 1999, Pages 216-221

  Desikan, K Raman ^a   Dhodapkar, Madhav V ^a   Munshi, Nikhil C ^a   Barlogie, Bart ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CANCER VACCINE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; TAMOXIFEN; THALIDOMIDE; VINCRISTINE;

AGE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PAIN; CANCER REGRESSION; CANCER RESISTANCE; CLINICAL FEATURE; CONSTIPATION; DRUG EFFICACY; DRUG MEGADOSE; GENETIC ASSOCIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA;

EID: 0032798144     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199907000-00004     Document Type: Review

References (56)

1. Hallek M, Bergsagel L, Anderson KC: Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998, 91:3-21.
2. Reboulissou C, Wijdenes J, Autissier P, Tarte K, Costes V, Liautard J, et al.: A gp 130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood 1998, 91:4727-4737.
3. Rettig MB, Ma HJ, Vescio RA, Pold M, Schiller G, Belson D, et al.: Kaposi's sarcoma associated herpes virus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997, 276:1951-1954.
4. Yi Q, Ekman M, Anton D, Bergenbrant S, Osterborg A, Hemming PG, et al.: Blood dendritic cells from myeloma patients are not infected with Kaposi's sarcoma associated herpesvirus. Blood 1998, 92:402-404.
5. Tarte K, Olsen SJ, Lu ZY, Legouffe E, Rossi JF, Chang Y, Klein B: Clinical grade dendritic cells from patients with multiple myeloma are not infected with kaposis sarcoma-associated herpesvirus. Blood 1998, 91:1852-1857.
6. Cathomas G, Regamey N, Stalder A, Kurrer MO, Joller-Jemelka HI, Erb P: Multiple myeloma and HHV-8 infection. Blood 1998, 91:4391.
7. Agbalika F, Mariette X, Marolleau JP, Fermand JP, Brouet JC: Detection of human herpesvirus-8 DNA in bone marrow biopsies from patients with multiple myeloma and waldenstoms macroglobulinemia. Blood 1998, 91:4393-4394.
8. Burger R, Neipel F, Fleckenstein B, Savino R, Ciliberto G, Kalden JR, Gramatzki M: Human herpesvirus interteukin-6 homologue is functionally active on human myeloma cells. Blood 1998, 91:1858-1863.
9. Dhodapkar MV, Abe E, Theus A, Lacy M, Langford JK, Barlogie B, Sanderson RD: Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth and bone cell differentiation. Blood 1998, 91:2679-2688.
10. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F: Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994, 87:503-508.
11. Munshi N, Wilson CS, Penn J, Epstein J, Singhai S, Hough A, et al.: Angiogenesis in newly diagnosed multiple myeloma: poor prognosis with increased microvessel density in bone marrow biopsies. Blood 1998, 92:98a.
12. Bellamy WT, Richter L, Frutgier Y, Grogan TM: Expression of vascular endothelial growth factor and its receptor in hematopoietic malignancies. Cancer Res 1999, 59:728-733.
13. Seildel C, Borset M, Turesson I, Abildgaard N, Sundan A: Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. Blood 1998, 91:806-812.
14. Cigudosa JC, Rao PH, Jose Calasanz M, Dolores Odero M, Michaeli J, Jhanwar SC, Chaganti RSK: Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 1998, 91:3007-3010.
15. Chesi M, Bergsagel PL, Oluwatoyin O, Shonukan OO, Martelli ML, Brents LA, et al.: Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998, 91:4457-4463.
16. Sawyer JR, Lukacs JL, Munshi N, Desikan KR, Singhal S, Mehta J, et al.: Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood 1998, 92:4269-4278.
17. Perez-Sirnon JA, Garcia-Sanz R, Tabemero D, Almeida J, Gonzalez M, Fernandez-Calvo J, et al.: Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood 1998, 91:3366-3371.
18. Giesler F, Nubler V: Cellular resistance mechanisms with impact on the therapy of multiple myeloma. Leukemia 1998, 12:1009-1012.
19. Pilarski LM, Yatscoff RW, Murphy GF, Belch AR: Drug resistance in multiple myeloma: cyclosporin A analogues and their metabolites as potential chemosensitizers. Leukemia 1998, 12:505-509.
20. Case DC, Jain V, Stiff P, Jansen J, Stewart AK, Shurafa M, et al.: Phase II study of PSC833 and VAD chemotherapy in VAD refractory multiple myeloma. Blood 1998, 92:105a.
21. Raaijmakers HGP, Izquierdo MAI, Lockhorst HM, de Leeuw C, Belien JAM, Bloem AC, et al.: Lung resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 1998, 91:1029-1036.
22. Kraut EH, Crowley JJ, Wade JL, Laufman LR, Alsina M, Taylor SA, Salmon SE: Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1998, 16:589-592.
23. Dammacco F, San Miguel JF, Attal M, Jost L, Gimsing P, Rossi JF, et al.: Vinorelbine plus high dose dexamethasone for treatment of relapsing multiple myeloma: a phase II study. Blood 1998, 92:319a.
24. Mohrbacher A, Gregory S, Justice G, Schlutz M, Roberts L, Chen D, Giles FG: Liposomal daunorubicin is effective therapy for multiple myeloma. Blood 1998, 92:110a.
25. Berenson J, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al.: Long term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998, 16:593-602.
26. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A: In vitro cytoreductive effects on multiple myeloma cells induced by bisphosponates. Leukemia 1998, 12:220-229.
27. Yaccoby S, Barlogie B, Epstein J: Pamidronate inhibits growth of myeloma in the SCID-hu system. Blood 1998, 92:106a.
28. Dhodapkar MV, Singh J, Mehta J, Fassas A, Desikan R, Perlman M, et al.: Anti-myeloma activity of Pamidronate. Br J Haematol 1998, 103:530-532.
29. Berenson J, Webb I, Henick K, Vescio R, Swift R, Anderson K, Seaman J: A phase II dose-ranging trial of single agent pamidronate for relapsed/refractory multiple myeloma. Blood 1998, 92:107a.
30. Singhal S, Mehta J, Eddlemon P, Gray P, Cromer J, Desikan R, et al.: Marked anti-tumor effect from anti-angiogenesis therapy with thalidomide in high risk refractory multiple myeloma. Blood 1998, 92:318a.
31. Treon SP, Teoh G, Urashima M, Ogata A, Chauhan D, Webb LJ, Anderson KC: Anti-estrogens induce apoptosis of multiple myeloma cells. Blood 1998, 92:1749-1757.
32. Fermand JP, Labaume S, Rousselot P, Chopin M, Dosquet C, Poupon J, et al.: Arsenic trioxide and melarsoprol are effective in the treatment of human myeloma cells transplanted in SCID mice. Blood 1998, 92:109a.
33. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet G, Rossi JF, et al.: High dose therapy in multiple myeloma: an updated analysis of the IFM 90 protocol. Blood 1997, 90:418a.
34. Barlogie B, Jagannath J, Desikan KR, Vesole D, Siegel D, Tricot G, et al.: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1998, 92:4312-4324.
35. Attal M, Payen C, Fac;on T, Michaux JL, Guilhot F, Moconduit M, et al.: Single versus double transplant in myeloma: a randomized trial of the Intergroupe Français du Myelome (IFM). Blood 1997, 90:418a.
36. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al.: High dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998, 92:3131-3136.
37. Abonour R, Scott KM, Kunkel LA, Robertson MJ, Hromas R, Graves V, et al.: Autologous transplantation of mobilized peripheral blood CD 34+ cells selected by immunomagnetic procedures in patients with multiple myeloma. Bone Marrow Transplant 1998, 22:957-963.
38. Tricot G, Gazitt Y, Leemhuis T, Jagannath S, Desikan KR, Siegel D, et al.: Collection, tumor contamination and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood 1998, 91:4489-4495.
39. Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Engenhart R, Wannenmacher M, Haas R: Peripheral blood progenitor cell transplantation in multiple myeloma following high-dose melphalan-based therapy. Recent Results Clin Cancer 1998, 144:27-35.
40. Corso A, Klersy C, Lazzarino M, Bernasconi C: Multiple myeloma in younger patients: the role of age as prognostic factor. Ann Hematol 1998, 76:67-72.
41. Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N, et al.: Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999, 93:51-54.
42. Tricot G, Alberts DS, Johnson C, Roe DJ, Bracy D, Vesole DH, et al.: Safety of autotransplants with high dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996, 2:947-952.
43. Mehta J, Ayers D, Mattox S, Singh J, Singhal S, Siegel D, et al.: High dose melphalan and autotransplantation in myeloma with renal impairment: a matched-pair comparison with patients without renal failure. Blood 1998, 90:419a.
44. Desikan KR, Dhodapkar MV, Hough A, Waldron T, Jagannath S, Siegel D, et al.: Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma 1997, 27:315-319.
45. Bjorkstrand B, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, et al.: Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996, 88:4711-4718.
46. Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D, et al.: Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998, 21:887-892.
47. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disease. Blood 1998, 91:756-763.
48. Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, et al.: Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse afler allogeneic bone marrow transplant. Blood 1998, 91:3671-3680.
49. Blade J, San Miguel JF, Escudero ML, Fontanillas M, Besalduch J, Gardella S, et al.: Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology). Leukemia 1998, 12:1144-1148.
50. Bjorkstrand B, Svensson H, Ljungman P, Apperley J, Goldschmidt H, Remes K, et al.; 2522 autotransplants in multiple myeloma-a registry study from the European Group for Blood and Marrow Transplantation (EBMT). Blood 1997, 90:418a.
51. Powles R, Cunningham D, Malpas J, Raje N, Milan S, Viner C, et al.: A randomized trial of maintenance interferon following high dose chemotherapy in multiple myeloma: results 51/2 years after accrual of the last patient. Blood 1997, 90:356a.
52. Berenson J, Crowley J, Barlogie B, Salmon S: Alternate day oral prednisone therapy improves progression free and overall survival in multiple myeloma patients. Blood 1998, 92:318a.
53. Desikan R, Siegel D, Fassas A, Mehta J, Singhal S, Munshi N, et al.: DCEP consolidation after tandem autotransplants in high risk multiple myeloma-improved prognosis compared to matched historical controls. Blood 1998; 92:660a.
54. Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, et al.: Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type 1, major histocompatibility complex-restricted CD8- and CD4-specific T-cell responses. Blood 1998, 91:2459-2466.
55. Kwak LW, Sternas LA, Jagannath S, Siegel D, Munshi NC, Barlogie B: T-cell responses elicited by immunization of multiple myeloma patients with idiotypic M-protein plus GM-CSF in remission after autologous transplantation (PSCT). Blood 1997, 90:579a.
56. Wen YJ, Ling M, Bailey-Wood R, Lim SH: Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res 1998, 4:957-962.